US Bancorp DE grew its stake in shares of Enovis Co. (NYSE:ENOV – Free Report) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,569 shares of the company’s stock after acquiring an additional 607 shares during the quarter. US Bancorp DE’s holdings in Enovis were worth $815,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D increased its position in Enovis by 15.4% during the third quarter. State of New Jersey Common Pension Fund D now owns 43,404 shares of the company’s stock valued at $1,869,000 after acquiring an additional 5,801 shares during the last quarter. Diamond Hill Capital Management Inc. lifted its stake in shares of Enovis by 7.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock worth $129,352,000 after purchasing an additional 218,660 shares during the period. Chartwell Investment Partners LLC grew its position in Enovis by 25.6% during the third quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company’s stock valued at $8,681,000 after buying an additional 41,089 shares during the period. Aigen Investment Management LP raised its position in Enovis by 5.1% in the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock worth $381,000 after acquiring an additional 430 shares during the period. Finally, Victory Capital Management Inc. lifted its position in Enovis by 14.3% during the third quarter. Victory Capital Management Inc. now owns 32,846 shares of the company’s stock valued at $1,414,000 after purchasing an additional 4,099 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC decreased their price objective on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th.
Enovis Stock Down 5.8 %
NYSE ENOV opened at $35.55 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a fifty day moving average of $43.90 and a two-hundred day moving average of $43.98. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -16.23 and a beta of 2.05. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79.
Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. On average, analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.
Enovis Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Read More
- Five stocks we like better than Enovis
- How to start investing in penny stocks
- How to Protect Your Portfolio When Inflation Is Rising
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 3 Stocks to Consider Buying in October
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOV – Free Report).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.